MARKET

PRTK

PRTK

Paratek Pharmace
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.870
+0.080
+4.47%
After Hours: 1.900 +0.03 +1.60% 16:41 05/27 EDT
OPEN
1.790
PREV CLOSE
1.790
HIGH
1.900
LOW
1.760
VOLUME
361.08K
TURNOVER
0
52 WEEK HIGH
11.24
52 WEEK LOW
1.680
MARKET CAP
101.87M
P/E (TTM)
-1.6235
1D
5D
1M
3M
1Y
5Y
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other publi...
GlobeNewswire · 05/16 20:05
BRIEF-Paratek Pharmaceuticals Announces First Quarter 2022 Revenue Of $24.9 Million
reuters.com · 05/04 22:12
Paratek Pharmaceuticals Q1 EPS $(0.35), Inline, Sales $24.90M Miss $27.15M Estimate
Paratek Pharmaceuticals (NASDAQ:PRTK) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate. This is a 10.26 percent increase over losses of $(0.39) per share from the same period last
Benzinga · 05/04 20:53
Paratek Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $24.86M misses by $2.29M
Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q1 GAAP EPS of -$0.35 in-line. Revenue of $24.86M (+51.3% Y/Y) misses by $2.29M. Anticipates its existing cash, cash equivalents and marketable securities of $79.1
Seekingalpha · 05/04 20:46
-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Posts Q1 Revenue $24.9M, vs. Street Est of $27.2M
MT Newswires · 05/04 17:08
Earnings Outlook For Paratek Pharmaceuticals
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Paratek Pharmaceuticals will report an earnings per share...
Benzinga · 05/03 20:43
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other publ...
GlobeNewswire · 05/02 20:05
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first qu...
GlobeNewswire · 04/26 20:05
More
No Data
Learn about the latest financial forecast of PRTK. Analyze the recent business situations of Paratek Pharmace through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PRTK stock price target is 18.50 with a high estimate of 30.00 and a low estimate of 11.00.
High30.00
Average18.50
Low11.00
Current 1.870
EPS
Actual
Estimate
-0.45-0.24-0.020.19
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 158
Institutional Holdings: 35.24M
% Owned: 64.69%
Shares Outstanding: 54.48M
TypeInstitutionsShares
Increased
37
2.82M
New
11
541.97K
Decreased
36
1.52M
Sold Out
11
262.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Executive Director
Michael Bigham
President
Adam Woodrow
Chief Executive Officer/Director
Evan Loh
General Counsel/Secretary
William Haskel
Other
Randall Brenner
Independent Director
Minnie Baylor-Henry
Independent Director
Thomas Dietz
Independent Director
Timothy Franson
Independent Director
Rolf Hoffmann
Independent Director
Kristine Peterson
Independent Director
Robert Radie
Independent Director
Jeffrey Stein
No Data
No Data
About PRTK
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.

Webull offers kinds of Paratek Pharmaceuticals Inc stock information, including NASDAQ:PRTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTK stock methods without spending real money on the virtual paper trading platform.